A Phase 1-2 First-in-Human Study of CX-2029 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors or Lymphomas.

Brief description of study

The study is being done to look at: • The possible side effects, safety and tolerability of CX-2029 • The highest dose of CX-2029 that can be taken safely (maximum tolerated dose, abbreviated as MTD). • Evidence of anti-cancer activity responses in patients receiving CX-2029, including how long patients live. • Whether or not your body develops antibodies to CX-2029 that may affect its ability to attach to your tumor (immunogenicity). • The amount of CX-2029 in your blood and how long CX-2029 stays in your body. • Whether certain markers of iron metabolism affect the safety or activity of CX-2029 in your body • Whether CX-2029 binds to its target (CD71) in your body • Levels of certain markers which might help characterize the cancer within your tumor, blood or urine (for some patients). • How much CX-2029 is actually active within the tumor (for some patients).

Clinical Study Identifier: s18-00093
ClinicalTrials.gov Identifier: NCT03543813
Principal Investigator: Elaine Shum.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.